WASHINGTON, D.C. (February 19, 2021) — The Association for Accessible Medicines and its members look forward to working with President Biden’s CMS Administrator-designee Chiquita Brooks-LaSure to enhance patient access to safe, effective and affordable generic and biosimilar medicines.
It will be critical for CMS, in working with Congress, to update the Medicare program in order to remove the perverse incentives that increase out-of-pocket costs for seniors and delay patient access to generics and biosimilars. Building on its previous policy solutions, AAM will release recommendations to fix these impediments to access in a new report, Securing Sustainable Markets, to be published on Monday.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.